Fulcrum Therapeutics, Inc. (FULC )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol FULC
- Company Fulcrum Therapeutics, Inc.
- Price $9.16
- Changes Percentage -15.89
- Change -1.73
- Day Low $8.76
- Day High $10.42
- Year High $15.74
- Year Low $2.32
- Market Cap $495,654,811
- Price Avg 50 EMA (D) $11.12
- Price Avg 200 EMA (D) $8.61
- Exchange NASDAQ
- Volume 2,258,063
- Average Volume 1,332,273
- Open $9.7
- Previous Close $10.89
- EPS -1.14
- PE -8.03
- Earnings Announcement 2026-02-24 14:30:00
- Shares Outstanding $54,111,378
Company brief: FULCRUM THERAPEUTICS, INC. (FULC )
- Healthcare
- Biotechnology
- Mr. Alexander C. Sapir
- https://www.fulcrumtx.com
- US
- N/A
- 07-18-2019
- US3596161097
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FULC Corporation News
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
globenewswire.com -- ― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―...
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
globenewswire.com -- ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular...